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database from a US national commercially-insured population (January 1, 2003-Sep-
tember 30, 2008). Women aged ≥18 were selected with ≥2 BC diagnoses on different 
dates within 90 days. The date of the ﬁrst BC diagnosis was the index date for case 
cohort. The control cohort (without BC diagnosis) was selected with a 3:1 ratio by 
matching to the cases based on index date (same year and month), age (5-year range), 
region, employer, and health insurance type. Both cohorts were required to have 
continuous enrollment for at least 6-months prior to and 12-months after the index 
date. Generalized linear model (GLM) was applied to evaluate the 1-year post-index 
cost difference between cases and controls with adjustment of demographics, comor-
bid conditions, and pre-index total health care cost. RESULTS: Based on the selection 
criteria, 140,228 patients were included with mean (SD) age of 52.1 (7.5) years. The 
total 1-year health care costs for cases and controls were $61,167 and $6,296, respec-
tively (p < 0.001). GLM predicted that the adjusted incremental health care cost was 
$42,401 (p < 0.001) per BC patient per year, which included 12%, 86%, and 2% for 
inpatient, outpatient, and prescription use. CONCLUSIONS: This study demonstrated 
that breast cancer is an expensive disease condition, which consumes on average 
$40,000 more per patient within the ﬁrst year of diagnosis for the US health care 
system. Most of the direct health care cost is spent in outpatient care settings.
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OBJECTIVES: Few data exist on the impact of breast cancer (BC) on absenteeism and 
short-term disability (STD) to employers. This study was undertaken to estimate BC 
related indirect cost impacts within the US population. METHODS: This was a ret-
rospective matched cohort study using a large health care claims database from a US 
national commercially-insured population (2003–2007). Women aged ≥18 were 
selected with ≥2 BC diagnoses on different dates within 90 days. The date of the ﬁrst 
BC diagnosis was the index date for case cohort. The control cohort (without BC 
diagnosis) was selected with 1:1 matching to cases based on index date (same year 
and month), age (5 year range), region, employer, and health insurance type. Continu-
ous enrollment for at least 6-months prior to and 12-months after the index date was 
required for both cohorts. Indirect cost was measured by days of absenteeism and 
STD, multiplied by age-matched average wage rates from Bureau of Labor Statistics. 
Two-part model was used to assess the 1-year post-index indirect cost difference 
between cases and controls with the adjustment of demographics, comorbid condi-
tions, and pre-index total health care cost. RESULTS: Based on the inclusion criteria, 
856 and 2668 patients were selected for absenteeism and STD outcomes, respectively. 
Costs of absenteeism were $4972 and $2937, and costs of STD were $7199 and $653 
for cases and controls, respectively, within the post-index year (both p < 0.001). Two-
part models predicted that the adjusted incremental costs for absenteeism and STD 
were $1911 and $6157 (p < 0.001) per BC patient per year. CONCLUSIONS: This 
study demonstrated that breast cancer is associated with approximately $8000 more 
in indirect cost per patient to the employer within the ﬁrst year of diagnosis.
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OBJECTIVES: Little is known about how resource utilization in the initial treatment 
period among advanced stage PCa patients differs between those receiving versus those 
not receiving chemotherapy, even for docetaxel, the earliest approved agent for meta-
static disease. METHODS: We analyzed patients aged 66 or older from the linked 
Surveillance, Epidemiology, and End Results & Medicare (SEER-Medicare) database. 
Patients were diagnosed with PCa between 2000 and 2005 and were followed until 
censoring. We restricted the cohort to patients with incident Stage IV disease (AJCC-
TNM classiﬁcation) and at least 24 months of post-diagnosis follow-up data. Initial 
costs (Medicare payments) were deﬁned as costs incurred from 2 months before 
diagnosis to 12 months post-diagnosis and patients were stratiﬁed according to whether 
they received chemotherapy, and subsequently, whether they received docetaxel. 
RESULTS: Application of the inclusion criteria resulted in 4,088 Stage IV PCa patients, 
of which 23% (N = 933) reported chemotherapy. Among chemotherapy users, 63% 
(N = 592) received docetaxel-containing regimens. Initial costs totaled $78.3M while 
PCa-speciﬁc initial costs totaled $49.9M. For the full sample (F), chemotherapy 
subsample (C), and no chemotherapy subsample (NC), the proportions of total costs 
attributed to PCa-speciﬁc inpatient costs (IC), non-PCa-speciﬁc IC, PCa-speciﬁc out-
patient costs (OC), non-PCa-speciﬁc OC, and other costs were distributed as follows: 
1) PCa-speciﬁc IC: F = 26.5% [$20.7M]; C = 23.4% [$4.7M]; NC = 27.5% [$16.0M] 
2) non-PCa-speciﬁc IC: F = 12.3% [$9.7M]; C = 10.3% [$2.1M]; NC = 13.1% [$7.6M] 
3) PCa-speciﬁc OC: F = 35.9% [$28.1M]; C = 42.1% [$8.5M]; NC = 33.8% [$19.6M] 
4) non-PCa-speciﬁc OC: F = 20.8% [$16.3M]; C = 22.5% [$4.5M]; NC = 20.1% 
[$11.7M] and 5) Other costs: F = 4.5% [$3.5M]; C = 1.7% [$0.3]; NC = 5.5% 
[$3.2M]. The proportion of PCa-speciﬁc outpatient costs was higher in the docetaxel 
subsample compared to the chemotherapy subsample. CONCLUSIONS: Among 
patients diagnosed with advanced disease, PCa-speciﬁc inpatient and outpatient costs 
accounted for two-thirds of Medicare payments, with PCa-speciﬁc outpatient costs 
gaining larger shares in the chemotherapy and docetaxel subsamples.
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OBJECTIVES: Metastatic Melanoma (MM) is associated with serious clinical and 
humanistic burden. This study calculated the cost and medical resource utilization 
attributable to MM in a large geographically diverse commercially insured US popula-
tion. METHODS: The MEDSTAT MarketScan® database (1/1/2000–12/31/2008) 
identiﬁed patients aged ≥18 years with ≥2 melanoma claims (ICD-9-CM 172.xx, 
V10.82), or ≥1 melanoma claim and ≥1 chemotherapies. After excluding patients with 
other malignant tumors and those with <1 month post-index or <6 months of pre-
index, 2 mutually exclusive cohorts were formed. Patients with diagnosis of metastasis 
or related chemotherapies were categorized as MM, and the remaining as non-MM. 
Index-date was the ﬁrst date of diagnosis of melanoma or MM respectively. Mean 
estimates of per-patient-per-month (PPPM) resource utilization and cost (in 2008 
dollars) within each group (pre vs. post) were statistically compared. Attributed cost 
of metastasis was the difference in mean differences (post-pre) between the groups. 
RESULTS: The study identiﬁed 407 MM and 13,796 non-MM patients (mean age 
48.8 and 47.8 years, respectively). For the MM patients, PPPM utilization increased 
3 to 12 times from the pre-metastatic period (inpatient: 0.007 to 0.090, emergency 
room: 0.010 to 0.044, ofﬁce: 0.724 to 2.592, all with p < 0.0001, and hospital out-
patient: 0.226 to 1.029, p = 0.0442), while the PPPM total cost increased 7 times 
($803.2 to $5,439.9, p < 0.0001). For the non-MM patients, utilization increased 
marginally following melanoma diagnosis (inpatient: 0.005 to 0.008, emergency 
room: 0.012 to 0.016, ofﬁce: 0.696 to 1.214, and hospital outpatient: 0.136 to 0.291, 
all p < 0.0001). The total cost for non-MM patients doubled following diagnosis of 
melanoma ($432.3 to $955.2, p < 0.0001). Upon metastasis, the disease attributed 
cost increased 9 times ($523 to $4638). CONCLUSIONS: The cost burden from 
resource utilization increases substantially with metastasis of melanoma. Treatments 
that signiﬁcantly delay disease progression in these patients will reduce this burden.
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OBJECTIVES: To estimate the health care costs, treatment patterns, and health care 
resource use in advanced ovarian cancer (aOC) patients receiving ﬁrst line chemo-
therapy. METHODS: Incident aOC patients between 2000–2005 were identiﬁed from 
the linked Surveillance, Epidemiology and End-Results (SEER)/Medicare data ﬁle using 
an ICD-9 code 56.9 with a “distant” tumor in the SEER staging variable. Women ≥65 
years at the time of aOC diagnosis (i.e. index date), with at least three months of data 
preceding the initial diagnosis were included. Subjects were followed from 30 days 
prior to index date until the ﬁrst occurrence of the following: receipt of a 2nd line treat-
ment given after a minimum of 90 days treatment free interval, death or the end of the 
Medicare claims data (i.e., December 2007). Measures of overall HRU included hospi-
talizations, outpatient visits, physician visits, hospice care, home health care, and 
skilled nursing facility utilization. Costs of each HRU event were estimated by summing 
all Medicare payments, primary insurer payments, patient copayments and deductibles 
for services in the claims ﬁles. Average health care costs per event per patient (e.g. 
hospitalization) are calculated as total cost per event divided by number of patients with 
the event. RESULTS: A total of 3895 aOC subjects receiving ﬁrst-line chemotherapy 
were included in the analysis. Mean age was 75 years. Carboplatin+paclitaxel (73%), 
carboplatin alone (8.5%), and carboplatin+docetaxel (7%) were the three most com-
monly used 1st line chemotherapeutic agents. The mean 1st line treatment duration was 
128 days (SD 95.8). The rate of hospitalization was 1.5 per person-year. Mean hospi-
talization cost per patient was $12,997 (SD $10,499). Mean SNF and Hospice Care 
costs per patient were $7,509 (SD $7,171) and $7,025 (SD $11,370) respectively. 
CONCLUSIONS: Carboplatin-paclitxel combination was the most commonly used 
ﬁrst line chemotherapeutic regimen. In aOC patients, hospitalization costs were sub-
stantial in women with aOC receiving 1st line chemotherapy.
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OBJECTIVES: To evaluate insurer and patient cost increases during the ﬁrst year 
following hepatocellular carcinoma (HCC) diagnosis. METHODS: Subjects in the 
Medstat MarketScan® claims database (July 1, 2005–June 30, 2008) were included 
for analysis if they were age ≥18 years, had ≥1 HCC claim (ICD9 155.0) from July 
1, 2006 to June 30, 2007, no cancer claims in the year prior to the ﬁrst HCC claim 
(index), and a full year of pre-index data. Per patient per month (PPPM) cost estimates 
were compared pre- and post- diagnosis with a sign rank test. RESULTS: The analyti-
cal dataset included 440 patients: mean age 53 years, 61% male, mean follow-up 256 
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days. Following HCC diagnosis, total insurer costs increased by 6-fold ($1695 v 
$9983; p < 0.0001) and total patient costs increased by 4-fold ($151 v $575; p < 
0.0008). For insurers, the majority of these increases were due to hospital visits: 56% 
due to an 8-fold increase in hospitalization costs ($668 v $5273; p < 0.0001), 1% due 
to a 3-fold increase in emergency room (ER) costs ($27 v $71; p = 0.66), and 23% 
due to a 6-fold increase in other hospital outpatient costs ($418 v $2359; p < 0.0001). 
Outpatient and other costs comprised 4–9% of the total cost increase. Similarly for 
patients, the majority of cost increases were due to hospital visits: 43% due to a 9-fold 
increase in hospitalization costs ($22 v $207; p < 0.0001), 0.25% due to a 20% 
increase in ER costs ($5 v $6; p = 0.35), and 38% due to a 5-fold increase in other 
hospital outpatient costs ($39 v $200; p < 0.0001). Outpatient and other costs com-
prised 5–7% of the total cost increase. CONCLUSIONS: Insurer and patient costs 
increase substantially following HCC diagnosis, primarily due to hospitalizations. 
Future therapies should demonstrate improved disease control to reduce this burden 
for insurers and patients.
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OBJECTIVES: To compare health care resource utilization and costs associated with 
dasatinib versus nilotinib treatment as second-line therapies in CML patients. 
METHODS: Two claims databases were combined (MarketScan and Ingenix Impact, 
January 2002–December 2008) to identify patients diagnosed with CML (ICD-9 code 
205.1x) and received ≥1 prescription of dasatinib or nilotinib. Patients were required 
to have continuous enrollment ≥1 month prior to and after the index date. The index 
date was deﬁned as the ﬁrst prescription for dasatinib or nilotinib. Patients were fol-
lowed for up-to 6 months from the index date to the earliest of the termination of 
health care plan enrollment, or end of data availability. Negative binomial regression 
models were used to compare health care resource utilization between the two groups. 
Results were reported as unadjusted and adjusted incidence rate ratios (IRR). Health 
care costs were compared and reported as unadjusted and adjusted cost differences. 
These were estimated for each cost component using generalized linear models or 
two-part models. Multivariate regressions controlled for age, gender, and CML disease 
complexity. RESULTS: A total of 230 CML patients receiving a second-line TKI (186 
dasatinib and 44 nilotinib) were studied. During the study period, dasatinib patients 
had signiﬁcantly more medical visits (IRR = 1.32, p = .028). Dasatinib patients had 
36% more hospital days but the difference was not statistically signiﬁcant (IRR = 1.36, 
p = 0.664). Over the 6–month follow-up period, patients on dasatinib incurred 
$18,328 (p < .001) more in total medical services and $6,367 (p = 0.04) less in phar-
macy costs, resulting in a higher net total health care cost of $12,039 (p = .035). The 
difference in medical costs was mainly explained by the difference of inpatient costs 
($12,480; p = < .001) and outpatient costs ($5,035; p = .001). CONCLUSIONS: 
Among CML patients treated with a second-line TKIs, dasatinib patients incurred 
higher total health care costs and more frequent health care resource utilization than 
nilotinib patients.
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OBJECTIVES: To study health care resource utilization and costs associated with 
long-term non-adherence to imatinib in CML patients. METHODS: Two large admin-
istrative claims databases were combined (MarketScan and Ingenix Impact, January 
2002-July 2008) to identify patients diagnosed with CML (ICD-9 code 205.1x). 
Patients with ≥2 imatinib prescriptions and continuous enrollment (≥6 months prior 
to and ≥1month post index date) were selected. Patients were followed for up to 3 
years after the index date. A longitudinal retrospective open-cohort design was used 
to measure patients’ adherence to imatinib repeatedly over time. Imatinib treatment 
periods were divided into 90-day intervals. Treatment intervals were categorized as 
adherent (MPR ≥85%) or non-adherent (MPR < 85%). Patients’ health care utilization 
and costs were compared between adherent and non-adherent intervals. Multivariate 
regression models were used to compare rates of inpatient admissions, outpatient 
visits, and emergency room visits, controlling for clinical and demographic character-
istics. Additional regression models including past cumulative MPR were used to 
assess the long-term impact of non-adherence. RESULTS: For the 1877 CML patients 
in the study, there were 6175 adherent and 3163 non-adherent intervals. Only 34% 
of patients were fully adherent throughout the observation period. During non-
adherent intervals, patients incurred signiﬁcantly more inpatient (IRR = 2.76, p < 
0.001), ER (IRR = 1.25, p = 0.021), and outpatient (IRR = 1.09 p = 0.001) visits. 
Though non-adherence was associated with lower pharmacy cost ($3053 p < 0.001), 
this difference was outweighed by higher medical costs ($4531 p < 0.001), resulting 
in a net cost increase ($1477 (p < 0.001). Patients who were adherent throughout 
their observation period incurred an average cost of $11,759 per interval, compared 
to $13,773 for patients who were not always adherent. In patients who had not 
always been adherent (past cumulative MPR < 85%) an adherent interval cost $1,239 
(p = .002) more, while another non-adherent interval cost $2122 (p < 0.001) more 
compared to an adherent interval in patients who had been adherent. CONCLU-
SIONS: Imatinib non-adherence is associated with long-term negative economic 
consequences.
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OBJECTIVES: Alemtuzumab has been demonstrated to reduce the amount of malig-
nant lymphocytes in patients with chronic lymphocytic leukemia (CLL). The current 
study aimed to quantify the incremental cost to Medicare of treating CLL patients 
with alemtuzumab. METHODS: Claims records (1999–2007) from the Medicare 5% 
national sample were analyzed. Patients with continuous enrollment for ≥3 months 
prior to their ﬁrst observed claim with a CLL diagnosis, ≤2 malignancies, and ≥1 claim 
for alemtuzumab were included. A pre-post design was used to quantify the incremen-
tal costs associated with alemtuzumab by calculating health care costs within 6 months 
after alemtuzumab initiation relative to the 6-month period before alemtuzumab initia-
tion. Mean monthly (per-patient per-month, PPPM) costs were calculated and were 
grouped by sites of care, service type, tests and procedures, treatment and drugs, and 
by adverse events. Statistical comparisons between the pre- and post-treatment periods 
were based on paired Student t-tests. RESULTS: A total of 81 CLL patients treated 
with alemtuzumab formed the study population. The mean age was 75.2 years and 
females represented 38.3%. Patients were observed for an average of 50 months and 
mean time between the ﬁrst CLL diagnosis and initiation of alemtuzumab treatment 
was 36 months. After alemtuzumab initiation, mean total health care costs increased 
from $4,272 to $10,385 PPPM (P < 0.0001). Patients had a mean of 11.8 claims for 
alemtuzumab and the mean cost for alemtuzumab was $4,006 PPPM or 39% of total 
costs. PPPM costs associated with diagnostic codes for cytopenia, infection, and 
cardiac dysfunction were greater during the post- compared with the pre-alemtuzumab 
period (cytopenia: $1,658 vs. $4,114; infection: $107 vs. $841; cardiac dysfunction: 
$766 vs. $1,692; P < 0.05 for all). CONCLUSIONS: Amongst a cohort of Medicare 
fee-for-service patients with CLL, alemtuzumab was associated with a signiﬁcant 
increase in health care costs in the 6 months after initiation of therapy.
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OBJECTIVES: This study estimates the costs of AIs sunitinib, sorafenib, and bevaci-
zumab using economic modeling based on recorded health care resource utilization 
from medical charts. METHODS: Non-trial mRCC patients, ≥18 years, who received 
≥1 prescription for sunitinib (n = 57) or sorafenib (n = 62) or ≥1 intravenous admin-
istration of bevacizumab (n = 25) after Janaury 1, 2005 as ﬁrst-line AI were included. 
Total per-patient-per-month (PPPM) costs (US$2008) included costs of AI drugs, 
ofﬁce visits, procedures, and treatment of adverse events (AE) resulting in hospitaliza-
tion or emergency room (ER) visits. AI drug costs were estimated by applying Average 
Wholesale Price to each patient’s observed treatment course (initial dose, dose changes, 
and treatment duration). Ofﬁce visit and procedure costs were based on US private 
insurance reimbursement. Hospitalization costs were based on HCUP National Inpa-
tient Sample average charges associated with AE diagnosis; cost-to-charge ratios were 
applied. ER visit costs were based on national averages from Medical Expenditure 
Panel Survey. RESULTS: Median treatment duration was10.5 months (sunitinib), 8.1 
months (sorafenib), and 7.9 months (bevacizumab). Total health care costs PPPM 
(mean ± SD) were $7,945 ± 2,993 (sunitinib), $6,990 ± 3,073 (sorafenib), and $15,189 
± 1,859 (bevacizumab). AI drug costs comprised 71% (sunitinib), 75% (sorafenib), 
and 90% (bevacizumab) of the total PPPM cost. All-grade AE costs PPPM were $729 
± SD (sunitinib), $636 ± SD (sorafenib), and $291 ± SD (bevacizumab). Given the 
median treatment durations, the total cost over the course of ﬁrst-line AI treatment is 
estimated at $83,422 (sunitinib), $56,622 (sorafenib), and $119,996 (bevacizumab), 
including AE treatment cost of $7,656 (sunitinib), $5,149 (sorafenib), and $2,297 
(bevacizumab). CONCLUSIONS: AI drug cost was a major contributor to the total 
health care PPPM cost in patients with mRCC, especially for patients receiving beva-
cizumab. This retrospective study is limited by small sample sizes. Future studies 
examining comparative cost-effectiveness of these AIs are warranted to evaluate clini-
cal and economic effects of these AIs.
